The use of the medicine Ophtalmoferon for the treatment of conjunctivitis in patients with HIV-infection and tuberculosis

Mordyk A.V.

Omsk State Medical University

Bagisheva N.V.

Omsk State Medical University

Nebesnaya E.Yu.

Omsk State Medical University

Khlebova N.V.

Clinical Anti-tuberculosis Hospital No. 4

Sitnikova S.V.

Clinical Anti-tuberculosis Hospital No. 4

Nesterova K.I.

Omsk State Medical University

Trukhan D.I.

Omsk State Medical University

Moiseeva M.V.

Omsk State Medical University

The use of the medicine Ophtalmoferon for the treatment of conjunctivitis in patients with HIV-infection and tuberculosis

Authors:

Mordyk A.V., Bagisheva N.V., Nebesnaya E.Yu., Khlebova N.V., Sitnikova S.V., Nesterova K.I., Trukhan D.I., Moiseeva M.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(4): 82‑89

DOI: 10.17116/oftalma202113704182

Downloaded: 32

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Mordyk AV, Bagisheva NV, Nebesnaya EYu, et al. . The use of the medicine Ophtalmoferon for the treatment of conjunctivitis in patients with HIV-infection and tuberculosis. Russian Annals of Ophthalmology. 2021;137(4):82‑89. (In Russ.)
https://doi.org/10.17116/oftalma202113704182

Подписка 2025 (Russian Annals of Ophthalmology)

Close metadata

PURPOSE

To assess the effectiveness of the medicine Ophtalmoferon (eye drops) in the treatment of conjunctivitis of mixed aetiology in patients with first-time tuberculosis (TB) and human immunodeficiency virus (HIV) infection, who have been treated at the Clinical Anti-tuberculosis Hospital No. 4

MATERIAL AND METHODS

The study included 60 patients (42 men and 18 women with mean age of 41.48±1.34 years), who had consulted the ophthalmologist for conjunctivitis. The patients were divided into two groups: the first group — main one (n=32) — received complex local therapy with the medicine Ophtalmoferon; the second group (n=28) — control one — did not receive Ophtalmoferon as a part of complex local treatment. The treatment involved assessment of the effectiveness, tolerability and safety of the examined medicine.

RESULTS

Patient examinations were conducted on the first visit, then on the third, fifth and seventh day of treatment. On the third day of treatment as compared to the baseline the burning sensation and pain in the eyes were less severe; in the main group that received the medicine Ophtalmoferon (group 1) the number of patients describing these symptoms as mild (1 point) were 15.6% (pain) and 18.8% (burning), respectively (W=2.15; p=0.03). Severe lacrimation (3 points) remained in 5 (15.6%) patients. On the fifth day there were no main group patients with severe (3 points) or moderate (2 points) lacrimation. On the seventh day complete resolution of subjective symptoms was noted in 71.9% (group 1) and 42.9% (group 2) of patients (χ2=1.39; p=0.238), respectively. There was no lacrimation in 71.9% (group 1) and 35.7% (group 2) of patients (χ2=2.36; p=0.125), no eye redness was noted in 78.1% (group 1) and 28.6% (group 2) of patients (χ2=4.51; p=0.034), respectively.

CONCLUSION

The use of the combined medicine Ophtalmoferon in the complex local treatment of conjunctivitis of mixed aetiology in patients with tuberculosis and HIV infection helps to achieve a rapid relief of subjective and objective symptoms with good tolerability of the medicine.

Keywords:

conjunctivitis

patients with tuberculosis and HIV infection

Ophtalmoferon

eye drops

Authors:

Mordyk A.V.

Omsk State Medical University

Bagisheva N.V.

Omsk State Medical University

Nebesnaya E.Yu.

Omsk State Medical University

Khlebova N.V.

Clinical Anti-tuberculosis Hospital No. 4

Sitnikova S.V.

Clinical Anti-tuberculosis Hospital No. 4

Nesterova K.I.

Omsk State Medical University

Trukhan D.I.

Omsk State Medical University

Moiseeva M.V.

Omsk State Medical University

Received:

26.05.2021

Accepted:

22.06.2021

List of references:

Vorobyeva I. The role of Ophtalmoferon in the treatment of viral eye diseases in type 2 diabetes patients with diabetic retinopathy (literature review). Vrach. 2018;29(10):25-30 (In Russ.). https://doi.org/10.29296/25877305-2018-10-08
Maychuk DYu, Maychuk YuF. Ophtalmoferon — 15 years of widespread use in the treatment and prevention of infectious eye diseases. Infekcionnye bolezni: novosti, mnenija, obuchenie. 2017;(1):82-100 (In Russ.).
Maychuk YuF. Konjunktivity. Sovremennaja lekarstvennaja terapija [Conjunctivitis. Modern medical therapy]. Moscow: Thea; 2014 (In Russ.).
Perederij VA. Glaznye bolezni. Polnyj spravochnik [Eye diseases. Complete reference]. Moscow: Jeksmo; 2008 (In Russ.).
Ponomareva MN, Gnatenko LE, Saharova SV, Savina EE. Ophthalmic manifestations in HIV infection (clinical case). Medicinskaja nauka i obrazovanie Urala. 2018;(1):109-113 (In Russ.).
Khijniak TV, Astakhov YuS, Rakhmanova AG. Ophthalmic involvement associated with the stage of HIV-infection. Oftal’mologicheskie vedomosti. 2009;(2):15-19 (In Russ.).
Maychuk YuF. Oftal’moferon. Opyt rasshirenija oblasti primenenija pri glaznyh zabolevanijah. M.; 2012. (In Russ.).
Nesterova KI, Nesterova AA. The effectiveness of topical antihistamine monotherapy in the patients with the manifestations of seasonal allergic rhinitis. Vestnik otorinolaringologii. 2015;(4):77-80 (In Russ.).
Trukhan DI, Fedotova OI, Pilipenko AV, Timchenko TS, Simontseva AA, Bagisheva NV, Mordyk AV, Goloshubina VV, Moiseeva MV. The experience of the medication Allergoferon in the treatment of insect bites. Jeffektivnaja farmakoterapija. 2020;(8):10-17 (In Russ.). https://doi.org/10.33978/2307-3586-2020-16-8-10-17
Surov AV, Zaspina AG. Complex treatment of allergic eye diseases using interferon alpha-2b and loratadine gel for topical and external use. Oftal’mologiya = Ophthalmology in Russia. 2014;11(1):62-65 (In Russ.). https://doi.org/10.18008/1816-5095-2014-1-62-65
Nadey EV, Sovalkin VI, Nesterova KI, Goltyapin VV. Efficiency of combined anti-inflammatory therapy and allergenspecific immunotherapy of comorbidity allergic bronchial asthma: one-factor dispersion analysis. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018;24(3):87-95 (In Russ.).
Haitov RM, Il’in NI, eds. Allergologija. Federal’nye klinicheskie rekomendacii [Allergology. Federal clinical guidelines]. Moscow: Farmarus Print Media; 2014 (In Russ.).
Mordyk AV, Bagisheva NV, Trukhan DI, Moiseeva MV, Nesterova KI, Nebesnaya EYu, Bakhshieva LI, Kazarikov NI, Kazarikova VE, Aroyan AR, Batishcheva TL, Antropova VV. Prevention and treatment of Acute Respiratory Viral Infections in patients with first-time tuberculosis. Infekcionnye bolezni. 2020;18(3):167-177 (In Russ.). https://doi.org/10.20953/1729-9225-2020-3-167-177
Surov AV, Korjakov SV. On the issue of prevention of infectious complications of the eyes after excimer laser operations. Medicinskij al’manah. 2015; 1(36):99-101 (In Russ.).
Chernakova GM, Kleshheva EA, Ovsjanko AA. Modern therapy of viral eye infections. Remedium Privolzh’e. 2014;4(124):1-33 (In Russ.).
Kononov AV, Livzan MA. Evidence-based medicine in the practice of a pathologist physician. Sibirskij Konsilium. 2002;(2):18-22 (In Russ.).]
Skornjakov SN, Shul’gina MV, Arijel’ BM, Balasanjanc GS, Vahrusheva DV, Vladimirov AV. Clinical practice guidelines for the etiological diagnosis of tuberculosis. Medicinskij al’jans. 2014;(3):39-58 (In Russ.).
Jablonskiy PK, ed. Ftiziatrija. Nacional’nye klinicheskie rekomendacii [Phthisiology. National clinical guidelines]. Moscow: GEOTAR-Media; 2015 (In Russ.).
Perel’man MI, ed. Ftiziatrija. Nacional’noe rukovodstvo [Phthisiology. National guideline]. Moscow: GEOTAR-Media; 2007 (In Russ.).
Slogotskaya LV, Bogorodskaya E, Ivanova D, Makarova M, Guntupova L, Litvinov V, Seltsovsky P, Kudlay DA, Nikolenko N. Sensitivity and specificity of new skin test with recombinant protein CFP10-ESAT6 in patients with tuberculosis and individuals with non-tuberculosis diseases. Eur Respir J. 2013;42(57):1995.
Slogotskaya LV, Bogorodskaya E, Sentchichina O, Ivanova D, Nikitina G, Litvinov V, Seltsovsky P, Kudlay DA, Nikolenko N, Borisov S. Effectiveness of tuberculosis detection using a skin test with allergen recombinant (CFP-10-ESAT-6) in children. Eur Respir J. 2015;46(59):4524.
Kudlay DA, Starshinova AA, Dovgalyuk IF. Recombinant tuberculosis allergen: 10 years of experience with the test in children and adolescents in the Russian Federation (meta-analysis data). Pediatrija. Zhurnal im. G.N. Speranskogo. 2020;99(3):121-129 (In Russ.). https://doi.org/10.24110/0031-403X-2020-99-3-121-129
Puzyreva LV, Safonov AD, Lebedev OI, Mordyk AV. Ocular tuberculosis. Vestnik oftal’mologii. 2016;132(3):103-107 (In Russ.). https://doi.org/10.17116/oftalma20161323103-107
Drapkina OM, Livzan MA, Martynov AI, Moiseev SV, Nikolaev NA, Skirdenko YuP. The first Russian expert consensus on the quantitative evaluation of the treatment adherence: pivotal issues, algorithms and recommendations. Medicinskij vestnik Severnogo Kavkaza. 2018;13(1-2):259-271 (In Russ.). https://doi.org/10.14300/mnnc.2018.13039

Close metadata